Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (25)

2022

  1. Immune–Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study

    Frontiers in Neurology, Vol. 13

  2. Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study

    Journal of Affective Disorders, Vol. 300, pp. 99-108

2019

  1. Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women

    Scientific Reports, Vol. 9, Núm. 1

  2. Non-HDL cholesterol as a therapeutic goal

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 28-33

  3. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

    Clinica e Investigacion en Arteriosclerosis

2018

  1. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

    Clinica e Investigacion en Arteriosclerosis, Vol. 30, Núm. 4, pp. 188-192

  2. Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome

    Oncotarget, Vol. 9, Núm. 4, pp. 4522-4536

2017

  1. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease

    Clinica e Investigacion en Arteriosclerosis

  2. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease

    Clinica e Investigacion en Arteriosclerosis

2014

  1. Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype

    FASEB Journal, Vol. 28, Núm. 12, pp. 5163-5171

2011

  1. Association between AT C573T polymorphism and cardiovascular risk factors in myocardial infarction

    Cardiovascular Pathology, Vol. 20, Núm. 3, pp. 156-161

2010

  1. Cocientes lipoproteicos: significado fisiológico y utilidad clínica de los índices aterogénicos en prevención cardiovascular

    Clinica e Investigacion en Arteriosclerosis, Vol. 22, Núm. 1, pp. 25-32

2009

  1. A novel mutation in DAX1 (NR0B1) causing X-linked adrenal hypoplasia congenita: Clinical, hormonal and genetic analysis

    Endocrine, Vol. 36, Núm. 2, pp. 275-280

  2. Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study

    Medicina Clinica, Vol. 132, Núm. 8, pp. 291-297

  3. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention

    Vascular Health and Risk Management

2007

  1. Management of dyslipidemia in the metabolic syndrome: Recommendations of the Spanish HDL-forum

    American Journal of Cardiovascular Drugs, Vol. 7, Núm. 1, pp. 39-58

2004

  1. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: Recommendations of HDL Forum

    American Journal of Cardiovascular Drugs, Vol. 4, Núm. 5, pp. 299-314

2000

  1. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 10, Núm. 1, pp. 1-6

1998

  1. A double blind, randomised, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring Type 2 diabetic patients

    Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 11, Núm. 4, pp. 242-248

  2. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism

    Mayo Clinic Proceedings, Vol. 73, Núm. 9, pp. 837-841